May 16, 2021 02:13 PM EDTUpdated May 17, 06:16 AM

#ACC21: Regeneron's Evkeeza shows promise in curbing high triglycerides, but will genetic disparities limit use?

Kyle Blankenship

When Regeneron scored an early approval for lipid lowering antibody Evkeeza back in February, the drugmaker cracked open a new pathway to lower abnormally high …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ACC21: Regeneron's Evkeeza shows promise in curbing high triglycerides, but will genetic disparities limit use?

Kyle Blankenship

Sign up to read this article for free.

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Agenus launches biologics manufacturing business to generate cash

#ACC21: Re­gen­eron's Evkeeza shows promise in curb­ing high triglyc­erides, but will ge­net­ic dis­par­i­ties lim­it use?

Kyle Blankenship

Sign up to read this article for free.

more like this

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing

Agenus launch­es bi­o­log­ics man­u­fac­tur­ing busi­ness to gen­er­ate cash

#ACC21: Regeneron's Evkeeza shows promise in curbing high triglycerides, but will genetic disparities limit use?

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Agenus launches biologics manufacturing business to generate cash